Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Molly T Beinfeld

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
JCO Oncology Practice|May 21, 2026
Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024Julia A Rucker, Molly T Beinfeld, Daniel Enright, et al.
Journal of Interventional Cardiology|October 6, 2005
A cost-effectiveness analysis of a hypothetical catheter-based strategy for the detection and treatment of vulnerable coronary plaques with drug-eluting stentsJohanna L Bosch, Molly T Beinfeld, James E Muller, et al.
Health Affairs Scholar|December 1, 2025
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savingsMolly T Beinfeld, Priyanka Ghule, Fariel LaMountain, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
JAMA|September 29, 2025
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene TherapiesJames D Chambers, Julia A Rucker, Daniel E Enright, et al.
Radiology|November 27, 2004
Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resectionG Scott Gazelle, Pamela M McMahon, Molly T Beinfeld, et al.
Health Policy OPEN|November 29, 2023
Variation in Medicaid and commercial coverage of cell and gene therapiesMolly T Beinfeld, Julia A Rucker, Nola B Jenkins, et al.
Health Affairs (Project Hope)|July 7, 2025
Drug Coverage Policies And Clinical Guidelines Alignment: Most Coverage Decisions Include Additional RestrictionsJulia A Rucker, Molly T Beinfeld, Katherine A Clifford, et al.
Health Affairs Scholar|May 17, 2024
Commercial coverage of specialty drugs, 2017-2021Julia A Rucker, Molly T Beinfeld, Nola B Jenkins, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
JCO Oncology Practice|May 21, 2026
Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024Julia A Rucker, Molly T Beinfeld, Daniel Enright, et al.
Journal of Interventional Cardiology|October 6, 2005
A cost-effectiveness analysis of a hypothetical catheter-based strategy for the detection and treatment of vulnerable coronary plaques with drug-eluting stentsJohanna L Bosch, Molly T Beinfeld, James E Muller, et al.
Health Affairs Scholar|December 1, 2025
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savingsMolly T Beinfeld, Priyanka Ghule, Fariel LaMountain, et al.
Health Affairs Scholar|July 28, 2025
What drug characteristics explain the wide range of manufacturer rebates?Molly T Beinfeld, Fariel LaMountain, Glenn Phillips, et al.
JAMA|September 29, 2025
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene TherapiesJames D Chambers, Julia A Rucker, Daniel E Enright, et al.
Radiology|November 27, 2004
Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resectionG Scott Gazelle, Pamela M McMahon, Molly T Beinfeld, et al.
Health Policy OPEN|November 29, 2023
Variation in Medicaid and commercial coverage of cell and gene therapiesMolly T Beinfeld, Julia A Rucker, Nola B Jenkins, et al.
Health Affairs (Project Hope)|July 7, 2025
Drug Coverage Policies And Clinical Guidelines Alignment: Most Coverage Decisions Include Additional RestrictionsJulia A Rucker, Molly T Beinfeld, Katherine A Clifford, et al.
Health Affairs Scholar|May 17, 2024
Commercial coverage of specialty drugs, 2017-2021Julia A Rucker, Molly T Beinfeld, Nola B Jenkins, et al.
Pageof 3